Radionuclide-antibody conjugates for single-cell cytotoxicity

Area of Science:

• Oncology
• Nuclear Medicine
• Immunotherapy

Background:

• Radioimmunotherapy traditionally uses high-energy beta-particles for macroscopic tumors.
• Current methods are inefficient for eliminating single cells or micrometastases.

Purpose of the Study:

• To review the use of radiolabeled antibody (Ab) conjugates for achieving single-cell kill.
• To discuss radionuclide selection, Ab localization, and clinical applications.

Main Methods:

• Selective review of literature on radiolabeled antibody conjugates.
• Analysis of radionuclide properties (alpha, beta, Auger, conversion electrons).
• Evaluation of antibody (Ab) binding and internalization effects.

Main Results:

• Auger and conversion electrons demonstrate high efficacy in single-cell kill (≥6 logs).
• Alpha-particles are effective but limited by short half-lives.
• Beta-particles can kill single cells but pose risks of nonspecific toxicity.

Conclusions:

• Single-cell kill is achievable with radionuclide-Ab conjugates.
• Auger and conversion electron emitters offer advantages for micrometastasis therapy.
• Optimal radionuclide choice depends on clinical factors; further comparisons are needed.